Change in Management
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 1.8 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board of Bandaram Pharma Packtech Limited met on 13 August 2026 and approved several items. These include unaudited financial results for Q1 FY27 (quarter ended 30 June 2026), re-appointment of Mr. Suryaprakasa Rao Bommisetti as Independent Director for a second 5-year term effective 7 March 2027, and re-appointment of M/s M.M. Reddy & Co. as statutory auditors for a 3-year term up to FY 2028-29. The board also approved the Director's Report for FY 2025-26 and fixed 18 September 2026 as the AGM date. On the numbers, standalone revenue jumped to Rs. 298.51 lakhs (from Rs. 75.74 lakhs a year ago) but the company reported a standalone net loss of Rs. 35.68 lakhs (vs Rs. 26.85 lakhs loss). On a consolidated level, revenue surged to Rs. 2,395.26 lakhs (from Rs. 810.37 lakhs) with a net profit of Rs. 68.44 lakhs (vs Rs. 2.47 lakhs), aided by subsidiaries VSR Paper and Packaging and Craftsmart Products.
For shareholders, this is largely a routine housekeeping update — re-appointments of an existing independent director and auditor signal continuity rather than change. The standalone business remains in the red even as revenue scales up sharply, while the consolidated picture turns profitable thanks to subsidiaries, which is worth watching closely in coming quarters.